Your browser doesn't support javascript.
loading
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
Wagner, Michael J; Othus, Megan; Patel, Sandip P; Ryan, Chris; Sangal, Ashish; Powers, Benjamin; Budd, G Thomas; Victor, Adrienne I; Hsueh, Chung-Tsen; Chugh, Rashmi; Nair, Suresh; Leu, Kirsten M; Agulnik, Mark; Sharon, Elad; Mayerson, Edward; Plets, Melissa; Blanke, Charles; Streicher, Howard; Chae, Young Kwang; Kurzrock, Razelle.
Affiliation
  • Wagner MJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA wagnermj@uw.edu.
  • Othus M; Medical Oncology, University of Washington, Seattle, Washington, USA.
  • Patel SP; SWOG Statistical and Data Management Center/Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Ryan C; Department of Medicine, UCSD Moores Cancer Center, La Jolla, California, USA.
  • Sangal A; Department of Medicine, OHSU, Portland, Oregon, USA.
  • Powers B; Western Regional Medical Center, Goodyear, Arizona, USA.
  • Budd GT; Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Victor AI; Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio, USA.
  • Hsueh CT; Department of Medicine, University of Rochester, Rochester, New York, USA.
  • Chugh R; Loma Linda University, Loma Linda, California, USA.
  • Nair S; Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Leu KM; Lehigh Valley Health Network, Allentown, Pennsylvania, USA.
  • Agulnik M; Nebraska Methodist Health System, Omaha, Nebraska, USA.
  • Sharon E; Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
  • Mayerson E; Department of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Plets M; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA.
  • Blanke C; SWOG Statistical and Data Management Center/Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Streicher H; SWOG Statistical and Data Management Center/Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Chae YK; Department of Medicine, OHSU, Portland, Oregon, USA.
  • Kurzrock R; SWOG, Portland, Oregon, USA.
J Immunother Cancer ; 9(8)2021 08.
Article in En | MEDLINE | ID: mdl-34380663
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Rare Diseases / CTLA-4 Antigen / Hemangiosarcoma Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: J Immunother Cancer Year: 2021 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Rare Diseases / CTLA-4 Antigen / Hemangiosarcoma Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: J Immunother Cancer Year: 2021 Document type: Article Affiliation country: Country of publication: